<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7392210\results\search\country\results.xml">
  <result pre="respectively [9], [10]). SARS-CoV first emerged in late 2002 in" exact="China" post="and spread rapidly to other parts of the world"/>
  <result pre="and spread rapidly to other parts of the world from" exact="Hong Kong" post="via air travel. The virus was believed to have"/>
  <result pre="(95% CI of 3.8â€&quot;8.9) and SI of 6â€&quot;9Â days in" exact="China" post="during the initial period of the outbreak [27]. In"/>
  <result pre="did not exhibit significant clinical benefits [38]. On April 29," exact="the US" post="NIH reported that in a high powered RCT of"/>
  <result pre="placebo group (15Â days) (pÂ [40] for COVID-19 patients in" exact="the United States." post="It has also been approved for therapeutic use in"/>
  <result pre="group (15Â days) (pÂ [40] for COVID-19 patients in the" exact="United States." post="It has also been approved for therapeutic use in"/>
  <result pre="in COVID-19 patients at the onset of the outbreak in" exact="China" post="before SARS-CoV-2 was identified as the etiologic factor. It"/>
  <result pre="an RNA-dependent RNA polymerase (RdRp) inhibitor. It is used in" exact="China" post="for the treatment of Influenza and is capable of"/>
  <result pre="been approved for experimental use in COVID-19 patients in Italy," exact="China" post="and Russia [54], [55]. In a recent multicenter trial"/>
  <result pre="for experimental use in COVID-19 patients in Italy, China and" exact="Russia" post="[54], [55]. In a recent multicenter trial in Japan,"/>
  <result pre="adverse effects or intolerance of the medication. A study in" exact="Brazil" post="(NCT04323527) was forced to prematurely halt patient recruitment due"/>
  <result pre="factor C5a. One trial (NCT04333420) is currently being held in" exact="the Netherlands" post="to test its efficacy in patients with severe COVID-19,"/>
  <result pre="C5a. One trial (NCT04333420) is currently being held in the" exact="Netherlands" post="to test its efficacy in patients with severe COVID-19,"/>
  <result pre="of the ACE2 is being studied on 200 participants in" exact="Austria" post="to determine if it can prevent viral entry and"/>
  <result pre="will include 3170 patients and will be conducted in the" exact="United Kingdom," post="with a completion date of March 30, 2021. 11"/>
  <result pre="plasma [77]. Another study on ten severely ill patients in" exact="China" post="showed that the clinical symptoms improved significantly within three"/>
  <result pre="Allergy And Infectious Diseases (NIAID) Phase II trial (NCT04405076) 600" exact="United States" post="August 2021 [83], [84] Lentiviral Minigene Vaccines (LV-SMENP-DC) Lentiviral"/>
  <result pre="Label Shenzhen Geno-Immune Medical Institute Phase I (NCT04276896) 100 Shenzen," exact="China" post="December 31, 2024 Bacillus Calmette-Guerin (BCG) live-attenuated vaccine* Live-attenuated"/>
  <result pre="(NCT04327206)ANDPhase III BCG-CORONA trial - (NCT04328441) 4,170 (Australia)AND1500 (Netherlands) AustraliaANDThe" exact="Netherlands" post="March 30, 2022ANDDecember 25, 2020 INO-4800 DNA plasmid vaccine."/>
  <result pre="trial (NCT04313127)ANDRandomized controlled phase II trial (ChiCTR2000031781) 108AND500 Wuhan, Hubei," exact="China" post="December 20, 2022 (Phase 1)ANDJanuary 2021 (Phase 2) AZD1222"/>
  <result pre="Single blinded University Of Oxford Phase II/III trial (NCT04400838) 10,260" exact="United Kingdom" post="August 2021 Pathogen-specific aAPC aAPCs modified with lentiviral vector"/>
  <result pre="Label Shenzhen Geno-Immune Medical Institute Phase I (NCT04299724) 100 Shenzen," exact="China" post="December 31, 2024 CoronaVac (Previously PiCoVacc) Formalin-InactivatedÂ +Â alum"/>
  <result pre="Outcomes Assessor) Sinovac Phase I (NCT04352608)ANDPhase II (NCT04383574). 143AND600 Jiangsu," exact="China" post="December 13, 2020 BNT162 Four mRNA vaccines: 2 nucleoside"/>
  <result pre="Open Label Pfizer and BioNtech Phase I/II (NCT04380701) 200 Berlin," exact="Germany" post="August 2020 Inactivated Vaccine Inactivated Novel Coronavirus Pneumonia vaccine"/>
  <result pre="ProductsANDChina National Pharmaceutical Group (Sinopharm) Phase I/II (ChiCTR2000031809) 1456 Wuhan," exact="China" post="November 2021 BBIBP-CorV Inactivated novel coronavirus (2019-CoV) vaccine (Vero"/>
  <result pre="Biological ProductsANDChina National Pharmaceutical Group (Sinopharm) Phase II (ChiCTR2000032459) 2128" exact="China" post="November 2021 GX-19 COVID-19 Preventive DNA Vaccine Randomized; Double"/>
  <result pre="Vaccine Randomized; Double blind Genexine Phase I/IIa (NCT04445389) 190 Seoul," exact="Republic of" post="Korea March 2021 Gam-COVID-Vac Non-replicating viral vector COVID-19 vaccine"/>
  <result pre="Contract Drug Research and Development Phase I (NCT04436471) 38 Moscow," exact="Russia" post="August 2020 mRNA-based vaccine SCB-2019 Non-chemically modified nucleotides within"/>
  <result pre="TBD** CureVacANDGerman federal government Phase I (Yet to commence) 168" exact="Germany" post="and Belgium TBD** SCB-2019 COVID-19 vaccine candidate that uses"/>
  <result pre="federal government Phase I (Yet to commence) 168 Germany and" exact="Belgium" post="TBD** SCB-2019 COVID-19 vaccine candidate that uses Clover's S-Trimer"/>
  <result pre="Clover Biopharmaceuticals, DynavaxÂ and Xiamen Innovax Phase I (NCT04405908) 150" exact="Australia" post="March 2021 COVAX-19 Monovalent recombinant protein vaccine Randomized; Triple"/>
  <result pre="Triple blind Vaxine Pty Ltd. Phase I (NCT04453852) 40 Adelaide," exact="Australia" post="July 2021 bacTRL-Spike Bifidobacteria monovalent SARS-CoV-2 DNA oral vaccine"/>
  <result pre="vaccine candidate Randomized; Triple blind Symvivo Phase I (NCT04334980) 112" exact="Canada" post="and United States December 2021 Covaxin (BBV152) Inactivated whole-virion"/>
  <result pre="Randomized; Triple blind Symvivo Phase I (NCT04334980) 112 Canada and" exact="United States" post="December 2021 Covaxin (BBV152) Inactivated whole-virion vaccine Randomized; Triple"/>
  <result pre="December 2021 Covaxin (BBV152) Inactivated whole-virion vaccine Randomized; Triple blind" exact="Bharat" post="BiotechANDNational Institute of Virology Phase I/II (NCT04471519) 1125 India"/>
  <result pre="blind Bharat BiotechANDNational Institute of Virology Phase I/II (NCT04471519) 1125" exact="India" post="June 2021 ZyCoV-D DNA-plasmid based vaccine TBD** Zydus Cadila"/>
  <result pre="vaccine TBD** Zydus Cadila Phase I/II (Yet to commence) 1048" exact="India" post="2021 *- Repurposed Vaccine; Original indication: Tuberculosis (TB) pediatric"/>
  <result pre="of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19" exact="Brasil" post="II) Experimental: HydroxychloroquineÂ +Â azithromycinHydroxychloroquine [400Â mg 2Ã—/day, 12/12Â"/>
  <result pre="53FurutaY.KomenoT.NakamuraT.Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymeraseProc." exact="Japan" post="Acad. Ser. B: Phys. Biol. Sci.932017449463 54Russian Ministry of"/>
  <result pre="a recipient of Junior Research Fellowship from University Grants Commission," exact="India" post="(UGC JRF Ref No: 190510369725). The Grant no. [SR/FST/LS-I/2017/05(C)]"/>
 </snippets>
</snippetsTree>
